| SYY |
Report |
USFS Local Case Volume Growth (%) |
BEAT |
pred ~3.0% vs cons 2.65% |
MEDIUM |
| SYY |
Report |
Adj. EPS (Diluted, Operating) |
IN-LINE |
pred ~$1.52 vs cons $1.5115 |
HIGH |
| SYY |
Report |
Gross Margin (%) |
IN-LINE |
pred ~18.85% vs cons 18.90% |
MEDIUM |
| SYY |
Guide |
Adj. EPS - FY2027 (initial) |
UNCHANGED |
guide ~$4.925 vs cons $4.929 |
MEDIUM |
| SYY |
Guide |
Local Case Volume - Q1 FY2027 (directional) |
BETTER |
guide 'at least 2.5%' vs cons ~2.17% |
HIGH |
| SYY |
Guide |
Revenue - FY2027 |
UNCHANGED |
guide ~$88-90B vs cons $88.47B |
MEDIUM |
| SYY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| SYY |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE - no estimate revision catalyst; JRD overhang reasserts; volume beat already priced into the +14% idiosyncratic pre-print run |
MEDIUM |